ACADIA Pharmaceuticals Inc. (ACAD)
ACAD moved a median of -0.14% 30 minutes after news, and -0.14% by the close. How ACAD actually reacts to news — the realized, point-in-time move the market made, measured across 392 labeled events over the last three years with zero look-ahead.
ACAD’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.04% | 51% | 392 |
| 30-min | -0.14% | 43% | 392 |
| 60-min | -0.15% | 46% | 392 |
| to close | -0.14% | 48% | 388 |
| Middle 50% of ACAD reactions | -1.04% to +0.77% |
|---|---|
| Median reaction (30-min) | -0.14% |
| Measured reactions | 392 |
Half of all ACADIA Pharmaceuticals Inc. news events land between -1.04% and +0.77% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ACAD reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 32 | +0.02% | 50% | -0.23% |
| Analyst downgrades | 21 | +1.33% | 67% | +0.88% |
| Coverage initiations | 28 | -0.38% | 36% | -0.02% |
| Rating reiterations | 164 | -0.10% | 44% | -0.04% |
| Price-target raises | 35 | -0.19% | 40% | +0.10% |
| Price-target cuts | 27 | -0.42% | 37% | -0.33% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how ACAD ranks against every other measured name →
That’s how ACAD usually reacts — get an email when it moves on news →Email me when ACAD moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ACAD's baseline. Nothing else.
Recent ACAD events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Encourages ACADIA Pharmaceuticals Inc. (ACAD) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.05% | -0.87% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages ACADIA Pharmaceuticals Inc. (ACAD) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.20% | -0.75% | |
| ACADIA Pharmaceuticals Inc. (ACAD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.05% | +0.36% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ACADIA Pharmaceuticals Inc. (ACAD) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.03% | -0.18% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating ACADIA Pharmaceuticals Inc. (ACAD) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | -0.23% | +1.77% | |
| ACADIA Pharmaceuticals Inc. (ACAD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.15% | -0.10% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ACADIA Pharmaceuticals Inc. (ACAD) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.07% | -0.74% | |
| Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041 | Press release | Business Wire | -0.79% | -0.74% | |
| Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP) | Press release | Business Wire | -6.32% | -9.02% | |
| Form 8-K ACADIA PHARMACEUTICALS For: Sep 24 | SEC filing · Form 8-K | SEC EDGAR | -1.31% | -6.89% | |
| Form 8-K ACADIA PHARMACEUTICALS For: Sep 11 | SEC filing · Form 8-K | SEC EDGAR | +0.25% | -1.57% | |
| European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union | Press release | Business Wire | -0.44% | +0.51% | |
| Form 10-Q ACADIA PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.38% | +2.86% | |
| Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results | Press release | Business Wire | +3.38% | +2.86% | |
| Form 8-K ACADIA PHARMACEUTICALS For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | +3.38% | +2.86% | |
| Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference | Press release | Business Wire | -1.89% | -2.16% | |
| Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis | Press release | Business Wire | -1.11% | -3.76% | |
| Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026 | Press release | Business Wire | -0.14% | -1.42% | |
| Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer | Press release | Business Wire | +0.45% | -0.12% | |
| DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP | Press release | Business Wire | +1.27% | -2.16% | |
| Form S-8 ACADIA PHARMACEUTICALS | SEC filing · Form S-8 | SEC EDGAR | -0.43% | +1.28% | |
| Form 8-K ACADIA PHARMACEUTICALS For: May 29 | SEC filing · Form 8-K | SEC EDGAR | -0.89% | +0.56% | |
| Form 10-Q ACADIA PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.46% | +3.06% | |
| Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance | Press release | Business Wire | +1.46% | +3.06% | |
| Form 8-K ACADIA PHARMACEUTICALS For: May 06 | SEC filing · Form 8-K | SEC EDGAR | +1.46% | +3.06% | |
| Form 8-K ACADIA PHARMACEUTICALS For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | -0.45% | -1.61% | |
| Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career | Press release | Business Wire | -0.45% | -1.61% | |
| Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences | Press release | Business Wire | +0.71% | -0.72% | |
| Form ARS ACADIA PHARMACEUTICALS For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.95% | -0.32% | |
| Form DEF 14A ACADIA PHARMACEUTICALS For: May 29 | SEC filing · Form DEF | SEC EDGAR | -0.95% | -0.32% | |
| Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting | Press release | Business Wire | +1.42% | +1.47% | |
| Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 | Press release | Business Wire | -0.62% | -2.79% | |
| Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome | Press release | Business Wire | -0.41% | -0.36% | |
| Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum | Press release | Business Wire | +0.12% | -3.74% | |
| Form 8-K ACADIA PHARMACEUTICALS For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | -0.81% | -2.06% | |
| Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors | Press release | Business Wire | -1.74% | +1.48% | |
| Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome | Press release | Business Wire | +0.13% | +0.72% | |
| Form 10-K ACADIA PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.23% | +5.62% | |
| Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview | Press release | Business Wire | +2.23% | +5.62% | |
| Form 8-K ACADIA PHARMACEUTICALS For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | +2.23% | +5.62% | |
| Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences | Press release | Business Wire | +0.32% | -1.80% | |
| Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 | Press release | Business Wire | -0.20% | -4.25% | |
| Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union | Press release | Business Wire | +0.76% | -3.62% | |
| Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | -0.72% | -1.85% | |
| Form 8-K ACADIA PHARMACEUTICALS For: Jan 13 | SEC filing · Form 8-K | SEC EDGAR | -0.06% | -0.06% | |
| Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 | Press release | Business Wire | +0.04% | +1.30% | |
| Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome | Press release | Business Wire | -0.23% | +1.50% | |
| Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference | Press release | Business Wire | -0.65% | +2.26% | |
| Form 10-Q ACADIA PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -7.44% | -8.19% | |
| Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview | Press release | Business Wire | -7.44% | -8.19% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ACAD section they belong to.
Where else ACAD is measured.
ACAD earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Kazia Therapeutics Limited - American Depositary Shares (KZIA) | 393 | -1.07% | 34% |
| OHR PHARMACEUTICALS (OHRP) | 393 | 0.00% | 48% |
| BioXcel Therapeutics, Inc. (BTAI) | 392 | -0.75% | 41% |
| Karyopharm Therapeutics Inc. (KPTI) | 392 | -0.45% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is ACADIA Pharmaceuticals Inc.'s median reaction calculated?
Every labeled ACAD news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 392 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of ACAD's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ACAD's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.